Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The RVPH news feed highlights the company’s progress in advancing its pipeline, particularly its lead candidate brilaroxazine (RP5063), which is being developed for schizophrenia and explored for additional indications such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
News updates commonly cover clinical trial milestones, including data from the Phase 3 RECOVER program in schizophrenia and its 1-year open-label extension. Reviva has reported broad-spectrum efficacy across major symptom domains, reductions in proinflammatory cytokines, and long-term safety and tolerability data for brilaroxazine. The company also releases information on biomarker research, such as vocal biomarker analyses that use speech latency to characterize negative symptoms and enrich antipsychotic clinical trials.
Regulatory and corporate developments are another key theme in RVPH news. Investors can follow announcements related to FDA interactions, including pre-New Drug Application (pre-NDA) feedback recommending a second Phase 3 trial in schizophrenia, as well as plans for the RECOVER-2 registrational study, subject to financing. Updates on Orphan Drug Designation for PAH and IPF, European patent grants for pulmonary fibrosis, and broader intellectual property strategy are also featured.
In addition, the news flow includes participation in scientific meetings, investor conferences, and key opinion leader events, where Reviva presents clinical and mechanistic data on brilaroxazine. For market participants tracking RVPH stock, this page consolidates company-issued press releases on clinical data, regulatory guidance, financing transactions, and strategic presentations in one place.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate presentation on Tuesday, September 30, 2025, at 10:15 AM ET.
The virtual event will include a corporate presentation and one-on-one meetings with management. Investors interested in scheduling meetings can contact Lytham Partners directly or register through the conference website.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced the pricing of a $9 million public offering. The offering includes 27 million shares of common stock (or equivalents) along with Series E and F warrants, priced at $0.335 per share and accompanying warrants.
The Series E warrants will expire in 5 years while Series F warrants will expire in 12 months, both with an exercise price of $0.335 per share. The offering is expected to close around September 22, 2025. Proceeds will support research and development activities and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will include shares of common stock (or equivalents) and warrants to purchase common stock, with A.G.P./Alliance Global Partners serving as the sole placement agent.
The proceeds will be used to fund research and development activities and for working capital purposes. The securities will be offered through an effective shelf registration statement on Form S-3. The completion of the offering is subject to market conditions, with no guaranteed size or terms.
Reviva Pharmaceuticals (NASDAQ: RVPH) has reported significant progress in its brilaroxazine development program for schizophrenia treatment, alongside Q2 2025 financial results. The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study, demonstrating sustained efficacy across all symptom domains and a well-tolerated safety profile.
Key clinical achievements include robust broad-spectrum efficacy with improvements in PANSS total score (-18.1), positive symptoms (-5.0), and negative symptoms (-4.4). The company plans to meet with the FDA in Q4 2025 to discuss the path to approval, with a potential NDA submission targeted for Q2 2026.
Financially, Reviva reported a net loss of $6.1 million ($0.12 per share) for Q2 2025, compared to $7.9 million in Q2 2024. The company's cash position stands at $10.4 million, bolstered by a recent $10.0 million public equity offering.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a $10 million public offering. The offering includes 20 million shares of common stock (or equivalents) at $0.50 per share, along with Series C and D warrants to purchase up to 20 million additional shares each.
The Series C warrants have a 5-year expiration while Series D warrants expire in 12 months, both with an exercise price of $0.50 per share. The offering is expected to close around June 27, 2025. Proceeds will fund R&D activities and general corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by A.G.P./Alliance Global Partners as the sole placement agent.
The company plans to use the proceeds to fund research and development activities and for working capital purposes. The securities will be offered under an effective shelf registration statement filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.
CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.